Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

PJ Online | News: Etoricoxib more effective than naproxen for rheumatoid arthritis

Home > PJ (current issue) > News / Daily News | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 269 No 7213 p273
31 August 2002

This article
Reprint
Photocopy


News summary

Related websites
Journal of Rheumatology article (more)


Etoricoxib more effective than naproxen for rheumatoid arthritis

The new cyclo-oxygenase-2 inhibitor Etoricoxib (Arcoxia) is more effective than naproxen for treating patients with rheumatoid arthritis, a study shows. Etoricoxib was launched earlier this year.

American researchers say that the superior efficacy of etoricoxib over naproxen, and placebo, was consistently observed over a range of measures, including tender and swollen joint counts and assessments of pain, inflammation, physical function and global disease activity. They add that etoricoxib was generally well tolerated in patients with rheumatoid arthritis.

They randomly assigned 816 patients who were chronic users of non-steroidal anti-inflammatory drugs to receive etoricoxib 90mg once daily, naproxen 500mg twice daily or placebo, for 12 weeks. Of these patients, 230 in the etoricoxib group (71.2 per cent), 96 in the naproxen group (55.2 per cent) and 122 taking placebo (37.8 per cent) completed the trial.

The most common reason for discontinuation was lack of efficacy and more patients in the naproxen group (36.5 per cent) and placebo group (54.5 per cent) discontinued for this reason than in the etoricoxib group (21. 7 per cent) (P<0.01 for etoricoxib versus placebo and naproxen).

Drug-related adverse events occurred most frequently in the digestive system, with patients in the naproxen group experiencing slightly higher incidences of dyspepsia, heartburn and nausea than patients in the other groups. The researchers conclude that the reason for etoricoxib's superior efficacy is unclear, as is whether or not the finding is a unique feature of the population studied (Journal of Rheumatology 2002;29: 1623). The study was funded by Merck Research Laboratories.

Back to Top

Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal

Citation: The Pharmaceutical Journal URI: 20007549

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Injectable Drugs Guide

    Injectable Drugs Guide

    A user friendly, single point of reference for healthcare professionals in the safe and effective administration of injectable medicines.

    £54.00Buy now
  • Good Pharmacovigilance Practice Guide

    Good Pharmacovigilance Practice Guide

    An essential guide on pharmacovigilance of medicinal products for human use. Practical advice for developing effective pharmacovigilance systems.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.